KarenLynn(Riedl)ReckampMDMS
Oncology • Los Angeles, CAThoracic Cancer
Director, Division of Medical Oncology Associate Director, Clinical Research, Cedars-Sinai Cancer
Dr. Reckamp is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
8700 Beverly Blvd
Los Angeles, CA 90048Phone+1 310-423-7197
Summary
- Dr. Karen Reckamp is an oncologist in Los Angeles, CA and is affiliated with Cedars-Sinai Medical Center. She received her medical degree from University of Chicago Pritzker School of Medicine and has been in practice over 15 years. She specializes in hematologic oncology and thoracic cancer and is experienced in lung cancer, thymic malignancies and mesothelioma.
Education & Training
UCLA David Geffen School of Medicine/UCLA Medical CenterFellowship, Hematology and Medical Oncology, 2001 - 2004
Washington University/B-JH/SLCH ConsortiumResidency, Internal Medicine, 1998 - 2001
University of Chicago Division of the Biological Sciences The Pritzker School of MedicineClass of 1998
Certifications & Licensure
CA State Medical License 2001 - 2026- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Super Doctor SuperDoctors.com
Clinical Trials
- Safety and Efficacy of Talactoferrin in Addition to Standard Chemotherapy in Patients With Non-small Cell Lung Cancer Start of enrollment: 2009 Feb 01
- PI3K Inhibitor BKM120, Carboplatin, and Pemetrexed Disodium in Treating Patients With Stage IV Non-Small Cell Lung Cancer Start of enrollment: 2013 Jul 01
- Ponatinib in Advanced NSCLC w/ RET Translocations Start of enrollment: 2013 Sep 01
- Join now to see all
Publications & Presentations
PubMed
- 629 citationsNivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials...Leora Horn, David R. Spigel, Everett E. Vokes, Esther Holgado, Neal Ready
Journal of Clinical Oncology. 2017-10-12 - 256 citationsEGFR-Mutant Adenocarcinomas That Transform to Small-Cell Lung Cancer and Other Neuroendocrine Carcinomas: Clinical OutcomesNicolas Marcoux, Scott N. Gettinger, Grainne M. O'Kane, Kathryn C. Arbour, Joel W. Neal
Journal of Clinical Oncology. 2019-02-01 - 355 citationsClinical Utility of Comprehensive Cell-free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non-small Cell Lung Cancer.Natasha B. Leighl, Ray D. Page, Victoria M. Raymond, Davey B. Daniel, Stephen G. Divers
Clinical Cancer Research. 2019-04-15
Lectures
- Germline mutations and onset of lung adenocarcinoma in smokers and nonsmokers.2019 ASCO Annual Meeting - 6/1/2019
- Brigatinib for Metastatic ALK Positive Non-Small Cell Lung Cancer. FDA Approvals and Their Incorporation into Clinical Practice2018 ASCO Annual Meeting - Chicago, Illinois - 06/1/2018
Authored Content
- Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung CancerAugust 2020
- Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung CancerAugust 2020
- Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung CancerAugust 2020
Press Mentions
A Closer Look at the Innovative Pragmatica-Lung TrialJuly 30th, 2024- Non-Small Cell Lung Cancer | Karen Reckamp, MD, MSJune 12th, 2024
- April Research HighlightsApril 28th, 2023
- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
